This is an observational study looking at how cognitive function (thinking and learning abilities) changes in people with Rett Syndrome (a rare genetic neurological disorder) when they start taking trofinetide. Researchers will use eye-tracking tasks to measure cognitive function and eye movements. This approach helps to assess abilities even when motor skills or verbal communication are challenging. The study aims to understand how trofinetide might affect these functions over time. You may be eligible if you are 18 years or older, have Rett Syndrome, and are starting trofinetide treatment through Gillette Children's RTT clinic. The study plans to include 20 participants.

Study design

This is an observational study, meaning researchers will watch and record information without giving any new treatments. It plans to include 20 participants.

What's involved

Cognitive function and eye movements will be measured at the beginning of the study and again between 6 weeks and 12 months later.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for cognitive function and eye movements for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.